Norwegian Contrasts
LATEST NEWS


Esben A. Nilssen steps down as CEO
15 February 2016
Esben A. Nilssen has informed the Board of Directors that he will step down as CEO of IC Targets within February 2016 to pursue other opportunities. Nilssen has been at the helm of IC Targets since the merger between IC Contrast and Epitarget in 2015. Håkon Sæterøy, currently Board member and majority shareholder, will assume the position as interim CEO.

Ludvik Sandnes and Jan Fikkan elected new members of the IC-T board

17 June 2015
Ludvik Sandnes and Jan Fikkan were elected new Chairman of the Board and board member, respectively, at the IC-T Annual General Meeting 16 June 2015. Ludvik has more than 40 years experience from international banking and corporate finance, while Jan recently has lead GE Healthcare’s 800 employee Norwegian organisation. Read more about our new board members here.

Annual General Meeting 16 June 2015 - Downloads
1 June 2015
The annual general meeting of ICTargets will be held at Oslo Science Park 16 June at 10 am.
Annual Report (only in Norwegian)
download.
AGM agenda
download.

IC Targets appoints Dr Sigrid L. Fossheim as Chief Operating Officer
17 April 2015
Sigrid brings along more than 15 years of cross-functional managerial experience spanning from innovative research, pharmaceutical drug development to due diligence and investments. She has had managerial positions in both multinational and start-up companies and was recently Head of Biotech Investments at the Norwegian Cancer Society. Sigrid has an Executive MBA from the Norwegian School of Economics (NHH), Bergen, an MSc Pharm and PhD degree, both from the University of Oslo. Learn more about the company’s new Chief Operating Officer here.
WHAT WE DO AT IC TARGETS


During MRI scans it is sometimes necessary to give the patient a substance to improve the clarity of the images. Such substances are called contrast agents and allow doctors to better identify disease. IC Targets develops a contrast agent helping cardiologists to select the patients benefiting from reopening of cardiac blood veins (revascularisation). This may lead to better care and reduced risk of heart failure. Clinical phase 2 trails are planned started early 2017.

IC Targets also conducts cancer therapy research on an immunostimulating substance called granulocyte colony stimulating factor (G-CSF). Our studies have shown that tumour growth is reduced when G-CSF is packed in small particles and co-administered with therapeutic antibodies. Animal studies are currently conducted in collaboration with French academic partners and the Norwegian Research Council.

The company is based in Oslo, Norway. Oslo is not only the global home of modern contrast agents, but has also a thriving immuno-oncology cluster.